Skip to main content

Month: January 2026

Lerøy Seafood Group ASA: Capital Markets Days 2026

Lerøy Seafood Group ASA has the pleasure of inviting investors, analysts and other stakeholders to its Capital Markets Days on March 2nd and 3rd, 2026. Management Presentations Management will present the Group’s strategic priorities, targets towards 2030, operational developments and capital allocation priorities at the Lerøy’s headquarters in Bergen, Norway, on March 2nd. A live webcast will be available at www.leroyseafood.com/capitalmarketsday The webcast will include a Q&A session with the possibility of submitting questions digitally. All presentations will be held in English. A Tour of the Salmon and Trout Value Chain Participants are invited to join a guided tour of Lerøy’s salmon and trout operations at Lerøy Sjøtroll in Austevoll on March 3rd. Request for Participation The management presentations on March 2nd will commence...

Continue reading

Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team

Pierrick Lefranc EVP Technical OperationsPierrick Lefranc appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026PARIS, FRANCE, 27 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan Murphy, EVP Technical Operations and Member of the ELT, who after 30 years of excellent service at Ipsen, will retire in March 2026. Pierrick brings over 30 years of experience in the pharmaceutical industry. Throughout his career, he has led manufacturing operations and large-scale industrial projects, consistently driving improvements in productivity, quality, and regulatory compliance. Since July 2019,...

Continue reading

IBA signs contract for a Proteus®ONE proton therapy system to be located at the MacKay Memorial Hospital in New Taipei City, Taiwan

Louvain-La-Neuve, Belgium, January 27, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be installed at the MacKay Memorial Hospital in New Taipei City, Taiwan. This is the fourth order of a Proteus®ONE system in Taiwan, further reinforcing IBA’s position as the undisputed market leader. The contract includes the delivery and the installation of a Proteus®ONE system as well as a comprehensive Quality Assurance package from IBA Dosimetry. As the market-leading compact proton therapy system, Proteus®ONE is designed to evolve and incorporate the latest technological advancements, ensuring...

Continue reading

Launch of the second phase of the Õielehe apartments development project (Rae parish, Estonia)

Õielehe apartment buildingÕielehe apartment building visualizationÕielehe terraced houseÕielehe terraced house visualizationOÜ Merko Kodud, part of the AS Merko Ehitus group, has decided to launch the second phase of the Õielehe development project in Rae parish in Jüri. As part of this, three apartment buildings with a total of 33 apartments will be completed in the spring of 2027 at the addresses Õie 6, Õie 8 and Õie 10. Sales of apartments will also begin in a five-apartment terraced house, which will be built at the address Õie 1. The sizes of the apartments in the two-story A-energy class apartment buildings of Õielehe homes (merko.ee/oielehe) range from 50 to 102 square meters, and prices per square meter start at 3,275 euros. The sizes of the two-story A-energy class apartments in the terraced house range from...

Continue reading

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau  54% of participants on the 24 mg dose achieved resolution of obesity (BMI

Continue reading

Mountain Lake Acquisition Corp. II Announces the Upsized Pricing of $313.2 Million Initial Public Offering

Incline Village, NV, Jan. 26, 2026 (GLOBE NEWSWIRE) — Mountain Lake Acquisition Corp. II (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chief Executive Officer Paul Grinberg and Chief Financial Officer, Douglas Horlick, today announced the pricing of its upsized initial public offering of 31,320,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at $11.50 per share. The units are expected to trade on the Global Market tier of the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “MLAAU” beginning January 27, 2026. No fractional warrants will be issued upon separation...

Continue reading

Fangzhou Issues Positive Profit Forecast as AI-Driven Chronic Care Model Delivers First Full-Year Profit

SHANGHAI, Jan. 27, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, issued a positive profit forecast for 2025, citing stronger-than-expected revenue growth and its first year of full profitability, underscoring the commercial viability of its “AI + chronic care services” model. In a filing released on January 25, the company said it expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%. Fangzhou also forecast a net profit of RMB 7 million to RMB 10 million, marking a transition to comprehensive profitability after achieving adjusted profitability in 2024. The company attributed the revenue increase primarily to the continued expansion of its chronic...

Continue reading

Fangzhou Raises HK$150 Million in Share Placement to Accelerate AI-Powered Chronic Care Platform

HONG KONG, Jan. 27, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has successfully completed a HK$150 million share placement, strengthening its balance sheet to accelerate investment in artificial intelligence and platform upgrades. The shares were priced at HK$3.32 per share, with the shares placed representing approximately 3.26% of the Company’s enlarged issued share capital following completion of the subscription. Fangzhou plans to allocate approximately 90% of the net proceeds after deducting related costs and expenses to accelerate development of the Company’s AI-driven chronic disease management platform. This encompasses model development and optimization, infrastructure and computational resource expansion, talent...

Continue reading

Twin Hospitality Group Files Voluntary Chapter 11 Petitions to Strengthen Capital Structure

DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) — Twin Hospitality Group Inc. (Nasdaq: TWNP), the parent company of Twin Peaks Restaurant, today announced it has commenced voluntary chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of Texas. Twin Hospitality plans to use the filings to deleverage the balance sheet, maximize value for its stakeholders, and support the continued growth of its brands. Twin Hospitality develops and operates the specialty casual dining restaurant concepts, Twin Peaks and Smokey Bones. Throughout the chapter 11 process, Twin Hospitality expects the brands will remain open and operating as usual and will continue delivering their signature guest experiences. Trading of Twin Hospitality Group’s securities on NASDAQ is expected to continue with a “Q” suffix during this period. “Twin...

Continue reading

Micron Breaks Ground on Advanced Wafer Fabrication Facility in Singapore

Approximately $24 billion investment over 10 years will support long-term manufacturing requirements and AI-driven demand SINGAPORE, Jan. 27, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) broke ground today on an advanced wafer fabrication facility located within the company’s existing NAND manufacturing complex in Singapore. This new facility represents a planned investment of approximately US $24 billion (SG $31 billion) over 10 years and is designed to ultimately provide 700,000 square feet of cleanroom space. Wafer output is scheduled to begin in the second half of calendar 2028, helping Micron address growing market demand for NAND technology driven by the rapid expansion of AI and data-centric applications. The groundbreaking ceremony for this facility, Singapore’s first double-story wafer manufacturing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.